News | January 20, 2026
Avalon clinches majority investment to expand future of diagnostic intelligence
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The move strengthens GBL’s clinical-stage presence in the United States
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
